drugset / Trial / NCT00199290
A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in order to verify the superiority of Trafermin to placebo, and to determine the recommended therapeutic dose.
Timeline
- Start
- 2005-08
- Primary completion
- 2007-07
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trafermin | Protein / enzyme biologic | 0.2 % | — |
| Subject | Trafermin | Protein / enzyme biologic | 0.3 % | — |
| Subject | Trafermin | Protein / enzyme biologic | 0.4 % | — |